What Is Leuphasyl? Benefits, Research & Safety
A 5-amino acid neuromuscular peptide that reduces expression lines through the enkephalin pathway, enhancing the effects of Argireline and SNAP-8.
UK summary: Cosmetic peptide regulated under UK cosmetics legislation. Enkephalin-pathway peptide marketed as an Argireline enhancer for expression lines. Effect size on its own is small.
Quick Facts
Overview
Leuphasyl — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Cosmetic peptide regulated under UK cosmetics legislation. Enkephalin-pathway peptide marketed as an Argireline enhancer for expression lines. Effect size on its own is small.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.
- EU: Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
- Notes: Leuphasyl (pentapeptide-18) is a fully approved cosmetic ingredient with established safety data. Despite working through enkephalin receptors, it has no opioid drug classification—effects are localised and cosmetic. Manufactured by Lubrizol (formerly Lipotec) and available globally in cosmetic formulations.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Equivalent to Botox.
- Reverses ageing topically.
07Common internet claims
- Marketed as enkephalin-pathway cosmetic peptide.
- Combined with Argireline / SNAP-8 in finished serums.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Synergistic with Argireline for wrinkles” | D | Limited | Moderate | Synergy claim is based on manufacturer studies; independent confirmation is limited. |
09Safety uncertainty score
Safety profile is well-characterised in published human data.
10Known adverse signals
- Generally well-tolerated topically.
- Rare skin sensitivity.
11Drug-interaction uncertainty
Drug-interaction picture documented in the prescribing information.
12Anti-doping status
13UK legal position
Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.
14EU legal position
Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
15What this page cannot tell you
- Whether independent finished-product trials demonstrate the manufacturer-claimed synergy.
- Effect magnitude vs retinoids in comparative trials.
16Last reviewed
17Citation quality score
18Research gaps
- Independent RCT data are limited; most positive findings are manufacturer-funded.
19Safer alternatives / established care pathways
- Daily sunscreen + topical retinoid.
- In-clinic botulinum toxin for genuine expression-line reduction.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate cosmetic addition to my routine?
- Are there more evidence-backed actives to combine?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Reduces expression lines through enkephalin pathway (distinct from Argireline)
- 2Enhances efficacy of Argireline/SNAP-8 when combined (synergistic effect)
- 3Up to 25% improved wrinkle reduction versus Argireline alone in studies
- 4Softens crow's feet, forehead lines, and frown lines
- 5Dual-pathway approach provides comprehensive neuromuscular modulation
- 6Excellent tolerability with rare side effects
- 7Compatible with all skin types including sensitive skin
- 8Suitable for use morning and evening
- 9Works independently if used alone
- 10No systemic opioid effects despite enkephalin receptor mechanism
Claim vs Evidence
How popular claims about Leuphasyl stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Synergistic with Argireline for wrinkles” | D | Limited | Moderate | Synergy claim is based on manufacturer studies; independent confirmation is limited. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Typically used at 3-8% concentration in topical formulations; often combined with Argireline or SNAP-8 at similar concentrations |
| Frequency | Applied twice daily to expression-prone areas (forehead, crow's feet, frown lines) |
| Duration | Visible improvements typically begin within 2-4 weeks; optimal results at 8+ weeks of consistent use |
| Notes | Leuphasyl is most effective when combined with Argireline or SNAP-8 for dual-pathway neuromuscular modulation. Apply to clean, dry skin on areas with expression lines before heavier products. Can be used morning and evening. For comprehensive anti-ageing, add collagen-stimulating peptides like Matrixyl to address structural ageing alongside expression line reduction. |
Administration Routes
Routes studied in research settings (educational only):
- Topical application in serums (most common)
- Topical application in multi-peptide anti-ageing formulations
- Topical application in eye contour treatments
- Topical application in targeted wrinkle treatments
| Half-Life | Stability |
|---|---|
| Effects persist while product remains on skin; must be applied consistently for maintained benefits; effects are cumulative with regular use | Stable in properly formulated cosmetic products; the D-Alanine in position 2 provides enzymatic stability; should be stored in cool, dark conditions; typically 12-24 month shelf life |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Very well tolerated—side effects are rare
- Mild skin irritation possible in sensitive individuals (uncommon)
- Temporary redness at application site (rare)
- Slight tingling sensation on initial application (occasional)
Rare Risks & Concerns
- Allergic reactions (very rare with peptides)
- Eye irritation if product enters eyes
- No systemic opioid effects at cosmetic concentrations
Contraindications
- Known allergy to peptides or specific formulation components
- Active skin infections at application site
- Open wounds (use only on intact skin)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.
🇪🇺 European Union
Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
Clinical Studies Summary
Synergistic Efficacy with Argireline
Studies examining Leuphasyl combined with Argireline showed enhanced wrinkle reduction compared to Argireline alone—approximately 25% improvement. The dual-pathway approach (enkephalin + SNARE) provided superior results to single-mechanism treatments.
Expression Line Reduction Study
Clinical evaluation of Leuphasyl formulations demonstrated significant reduction in periorbital and forehead expression lines over 28 days of twice-daily application. Participants showed visible improvement in dynamic wrinkle severity.
Enkephalin Receptor Mechanism Studies
In vitro studies confirmed Leuphasyl's mechanism by demonstrating binding to enkephalin receptors and subsequent reduction in neurotransmitter release from nerve terminal models. The mechanism is distinct from SNARE complex inhibition.
Dual-Pathway Combination Studies
Research on Leuphasyl + Argireline combinations demonstrated synergistic effects. The independent mechanisms (calcium channel modulation vs SNARE inhibition) work together to reduce muscle contraction through complementary pathways.
Safety and Tolerability Assessment
Cumulative safety data from commercial use demonstrates excellent tolerability with no significant adverse events. No systemic opioid effects were observed despite the enkephalin receptor mechanism—effects are localised to application site.
Looking for Leuphasyl?
Source research-grade Leuphasyl from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Leuphasyl
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate cosmetic addition to my routine?
- Are there more evidence-backed actives to combine?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreMatrixyl
A pioneering signal peptide that mimics natural collagen-boosting messengers, extensively validated in clinical studies for wrinkle reduction and skin firmness improvement.
Learn moreArgireline
A neuromodulating hexapeptide that reduces facial muscle contractions through SNARE complex inhibition, providing a topical alternative to botulinum toxin for expression line reduction.
Learn moreSNAP-8
An enhanced 8-amino acid version of Argireline with improved penetration and efficacy for reducing expression lines through SNARE complex modulation.
Learn moreSyn-Ake
A tripeptide that mimics the neuromuscular blocking effects of Temple Viper venom (waglerin-1), targeting nicotinic acetylcholine receptors to reduce expression lines.
Learn more